The practice of fecal microbiota transplantation in inflammatory bowel disease
Intestinal Research
; : 44-64, 2024.
Article
de En
| WPRIM
| ID: wpr-1043113
Bibliothèque responsable:
WPRO
ABSTRACT
Current evidence posits a central role for gut microbiota and the metabolome in the pathogenesis and progression of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been established as a means to manipulate this microbiome safely and sustainably. Several aspects of the technical improvement including pretreatment with antibiotics, use of frozen stool samples as well as short donor-to-recipient time are proposed to improve its response rates. Its efficacy in ulcerative colitis has been proven in clinical trials while data is emerging for Crohn’s disease. This review describes briefly the biology behind FMT, the available evidence for its use in IBD, and the host, recipient and procedural factors which determine the clinical outcomes.
Texte intégral:
1
Indice:
WPRIM
langue:
En
Texte intégral:
Intestinal Research
Année:
2024
Type:
Article